Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
acquired by Bain Capital and Cinven in 2017
|
| gptkbp:businessModel |
Aktiengesellschaft (AG)
|
| gptkbp:CEO |
Peter Goldschmidt
|
| gptkbp:country |
gptkb:Germany
|
| gptkbp:focusArea |
generics
OTC products |
| gptkbp:founded |
1895
|
| gptkbp:headquarters_location |
gptkb:Bad_Vilbel,_Germany
|
| https://www.w3.org/2000/01/rdf-schema#label |
STADA Group
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:ISIN |
DE0007251803
|
| gptkbp:market |
global
|
| gptkbp:notableBrand |
Aqualibra
Grippostad Ladival Hoggar Night |
| gptkbp:numberOfEmployees |
~12,300 (2023)
|
| gptkbp:officialWebsite |
https://www.stada.com/
|
| gptkbp:parentOrganization |
gptkb:Cinven
gptkb:Bain_Capital |
| gptkbp:products |
generic drugs
over-the-counter medications |
| gptkbp:revenue |
€3.7 billion (2022)
|
| gptkbp:stockExchange |
gptkb:Frankfurt_Stock_Exchange
|
| gptkbp:stockSymbol |
SAZ (delisted)
|
| gptkbp:bfsParent |
gptkb:Hemofarm
|
| gptkbp:bfsLayer |
8
|